Pasithea TherapeuticsKTTA
Market Cap: $5.42M
About: Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.
Employees: 8
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
17% more funds holding
Funds holding: 6 [Q1] → 7 (+1) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.01% less ownership
Funds ownership: 2.89% [Q1] → 2.88% (-0.01%) [Q2]
31% less capital invested
Capital invested by funds: $218K [Q1] → $152K (-$66.5K) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for KTTA.
Financial journalist opinion
Based on 3 articles about KTTA published over the past 30 days